Wells Fargo raised the firm’s price target on Humana (HUM) to $347 from $344 and keeps an Overweight rating on the shares. The firm is updating estimates and price targets in the space ahead of Q3 2025 results. Notability, Wells now assumes extension of enhanced subsidies is likely.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Positive Outlook for Humana: Buy Rating Supported by Strategic Initiatives and Growth Projections
- Humana updates outside of star ratings positive, says Mizuho
- Humana price target lowered to $245 from $315 at Barclays
- Humana’s Strategic Initiatives to Enhance Medicare Advantage Performance and Financial Margins